| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 3.72M | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | -3.72M | 0 |
| Gross Margin % | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | 1% |
| Operating Expenses | 10.1M | 37.19M | 112.9M | 185.73M | 138.39M | 96.42M | 70.4M |
| OpEx % of Revenue | - | - | - | - | - | - | - |
| Selling, General & Admin | 928K | 6.95M | 30.11M | 60.06M | 49.34M | 41.58M | 24.99M |
| SG&A % of Revenue | - | - | - | - | - | - | - |
| Research & Development | 9.17M | 30.24M | 82.79M | 117.67M | 86.05M | 59.56M | 40.18M |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 8M | 3M | -4.72M | 5.23M |
| Operating Income | -13.47M | -37.19M | -112.9M | -185.73M | -138.39M | -100.14M | -70.4M |
| Operating Margin % | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -1.76% | -2.04% | -0.65% | 0.25% | 0.28% | 0.3% |
| EBITDA | -7.42M | -37.05M | -112.1M | -184.19M | -134.72M | -96.42M | -67.32M |
| EBITDA Margin % | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -3.99% | -2.03% | -0.64% | 0.27% | 0.28% | 0.3% |
| D&A (Non-Cash Add-back) | 0 | 134K | 800K | 1.54M | 3.68M | 3.72M | 3.08M |
| EBIT | -12.77M | -36.69M | -111.9M | -177.73M | -135.39M | -102.06M | -65.17M |
| Net Interest Income | 0 | 696K | 670K | 343K | 2.27M | 5.6M | 4.3M |
| Interest Income | 0 | 696K | 670K | 343K | 2.27M | 5.6M | 4.3M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 696K | -8.45M | 670K | 343K | 2.27M | -1.93M | 5.63M |
| Pretax Income | -12.77M | -45.63M | -112.23M | -185.39M | -136.13M | -102.06M | -64.77M |
| Pretax Margin % | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -12.77M | -45.63M | -112.23M | -185.39M | -136.13M | -102.06M | -64.77M |
| Net Margin % | - | - | - | - | - | - | - |
| Net Income Growth % | - | -2.57% | -1.46% | -0.65% | 0.27% | 0.25% | 0.37% |
| Net Income (Continuing) | -12.77M | -45.63M | -112.23M | -185.39M | -136.13M | -102.06M | -64.77M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.60 | -45.60 | -57.80 | -69.51 | -50.00 | -37.29 | -21.44 |
| EPS Growth % | - | -3.3% | -0.27% | -0.2% | 0.28% | 0.25% | 0.43% |
| EPS (Basic) | -10.60 | -45.60 | -57.80 | -69.51 | -50.00 | -37.29 | -21.44 |
| Diluted Shares Outstanding | 1.2M | 1.2M | 2.28M | 2.67M | 2.72M | 2.74M | 3.02M |
| Basic Shares Outstanding | 1.2M | 1.2M | 2.28M | 2.67M | 2.72M | 2.74M | 3.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 33.4M | 165.78M | 317.18M | 325.07M | 197.04M | 117.96M | 78.81M |
| Cash & Short-Term Investments | 24.86M | 158.87M | 304.82M | 315.77M | 189.61M | 114.29M | 76.76M |
| Cash Only | 24.86M | 158.87M | 135M | 128.97M | 34.6M | 21.71M | 37.57M |
| Short-Term Investments | 0 | 0 | 169.81M | 186.81M | 155.01M | 92.58M | 39.18M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 8.44M | 6.75M | 10.96M | 1.73M | 926K | 923K | 838K |
| Total Non-Current Assets | 62K | 12.84M | 8.03M | 30.01M | 46.51M | 32.59M | 23.6M |
| Property, Plant & Equipment | 28K | 1.09M | 2.79M | 23.81M | 42.24M | 32.15M | 23.13M |
| Fixed Asset Turnover | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 34K | 11.75M | 5.23M | 6.2M | 4.27M | 433K | 463K |
| Total Assets | 33.46M | 178.61M | 328.01M | 355.08M | 243.55M | 150.54M | 102.41M |
| Asset Turnover | - | - | - | - | - | - | - |
| Asset Growth % | - | 4.34% | 0.84% | 0.08% | -0.31% | -0.38% | -0.32% |
| Total Current Liabilities | 307K | 3.68M | 21.18M | 29.5M | 18.35M | 16.34M | 19.36M |
| Accounts Payable | 212K | 629K | 5.26M | 9.45M | 4.07M | 1.3M | 742K |
| Days Payables Outstanding | - | - | - | - | - | 127.32 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 3.69M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7K | 46K | 541K | 661K | 85K | 6.64M | 10.53M |
| Current Ratio | 108.79x | 45.04x | 14.98x | 11.02x | 10.74x | 7.22x | 4.07x |
| Quick Ratio | 108.79x | 45.04x | 14.98x | 11.02x | 10.74x | 7.22x | 4.07x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 45.33M | 580K | 2.12M | 6.92M | 23.83M | 22.92M | 21.79M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 23.83M | 22.92M | 21.79M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 45.33M | 580K | 2.12M | 6.92M | 0 | 0 | 0 |
| Total Liabilities | 45.63M | 4.26M | 23.29M | 36.42M | 42.18M | 39.26M | 41.15M |
| Total Debt | 0 | 0 | 0 | 0 | 27.11M | 26.29M | 25.48M |
| Net Debt | -24.86M | -158.87M | -135M | -128.97M | -7.49M | 4.58M | -12.1M |
| Debt / Equity | - | - | - | - | 0.13x | 0.24x | 0.42x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | -12.17M | 174.35M | 304.71M | 318.66M | 201.37M | 111.28M | 61.26M |
| Equity Growth % | - | 15.32% | 0.75% | 0.05% | -0.37% | -0.45% | -0.45% |
| Book Value per Share | -10.16 | 145.52 | 133.60 | 119.47 | 73.99 | 40.66 | 20.28 |
| Total Shareholders' Equity | -12.17M | 174.35M | 304.71M | 318.66M | 201.37M | 111.28M | 61.26M |
| Common Stock | 2K | 3K | 4K | 5K | 5K | 5K | 6K |
| Retained Earnings | -13.03M | -58.66M | -170.9M | -356.28M | -492.41M | -594.47M | -659.24M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | -230.6K | -12K | -413K | -966K | -43K | 8K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.57M | -39.9M | -80.52M | -126.88M | -118.21M | -78.26M | -47.96M |
| Operating CF Margin % | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -1.15% | -1.02% | -0.58% | 0.07% | 0.34% | 0.39% |
| Net Income | -12.77M | -45.63M | -112.23M | -185.39M | -136.13M | -102.06M | -64.77M |
| Depreciation & Amortization | 0 | 134K | 800K | 1.54M | 3.68M | 3.72M | 3.08M |
| Stock-Based Compensation | 0 | 1.45M | 14.58M | 32.69M | 0 | 10.92M | 5.82M |
| Deferred Taxes | 0 | 0 | 633K | 2.78M | 0 | 0 | 0 |
| Other Non-Cash Items | 2.73M | 10.09M | 1.26M | 10.07M | 22.73M | 3.82M | 3.71M |
| Working Capital Changes | -8.52M | -5.94M | 14.44M | 11.42M | -8.49M | 5.34M | 4.2M |
| Change in Receivables | 212K | 398K | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 212K | 398K | 4.59M | 2.2M | -5.41M | -2.79M | -556K |
| Cash from Investing | -2.54M | -1.69M | -172.11M | -45.81M | 25.2M | 65.24M | 54.95M |
| Capital Expenditures | -2.54M | -1.19M | -1.65M | -25.64M | -5.27M | -146K | -34K |
| CapEx % of Revenue | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -2.52K | -500K | -500K | -8M | 0 | 0 | 0 |
| Cash from Financing | 45.97M | 175.6M | 228.75M | 166.66M | -1.35M | 135K | 8.87M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 0 | -587K | 284K | -37K | -1.79M | 0 | 132K |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -21.11M | -41.59M | -82.17M | -152.52M | -123.48M | -78.41M | -47.99M |
| FCF Margin % | - | - | - | - | - | - | - |
| FCF Growth % | - | -0.97% | -0.98% | -0.86% | 0.19% | 0.37% | 0.39% |
| FCF per Share | -17.62 | -34.71 | -36.03 | -57.18 | -45.37 | -28.65 | -15.89 |
| FCF Conversion (FCF/Net Income) | 1.45x | 0.87x | 0.72x | 0.68x | 0.87x | 0.77x | 0.74x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -56.28% | -46.85% | -59.48% | -52.35% | -65.29% | -75.07% |
| Return on Invested Capital (ROIC) | - | - | -91.45% | -77.52% | -54.12% | -48.49% | -63.99% |
| Debt / Equity | - | - | - | - | 0.13x | 0.24x | 0.42x |
| FCF Conversion | 1.45x | 0.87x | 0.72x | 0.68x | 0.87x | 0.77x | 0.74x |
Passage Bio, Inc. (PASG) grew revenue by 0.0% over the past year. Growth has been modest.
Passage Bio, Inc. (PASG) reported a net loss of $45.3M for fiscal year 2024.
Passage Bio, Inc. (PASG) has a return on equity (ROE) of -75.1%. Negative ROE indicates the company is unprofitable.
Passage Bio, Inc. (PASG) had negative free cash flow of $33.5M in fiscal year 2024, likely due to heavy capital investments.